TY - JOUR
T1 - Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence
AU - Nomura, Akira
AU - Ujike, Hiroshi
AU - Tanaka, Yuji
AU - Otani, Kyohei
AU - Morita, Yukitaka
AU - Kishimoto, Makiko
AU - Morio, Akiko
AU - Harano, Mutsuo
AU - Inada, Toshiya
AU - Yamada, Mitsuhiko
AU - Komiyama, Tokutaro
AU - Sekine, Yoshimoto
AU - Iwata, Nakao
AU - Sora, Ichiro
AU - Iyo, Masaomi
AU - Ozaki, Norio
AU - Kuroda, Shigetoshi
N1 - Funding Information:
The authors are grateful to the Zikei Institute of Psychiatry (Okayama, Japan) and the Ministry of Health, Labour and Welfare of Japan for support in part by grants.
PY - 2006/5/29
Y1 - 2006/5/29
N2 - Previous studies have indicated that genetic factors substantially affect development of substance use disorders, including methamphetamine dependence. Prodynorphin (PDYN) is an opioid peptide precursor that yields dynorphins, endogenous κ opioid-receptor agonists that play important roles in substance abuse. A physiologically active polymorphism of 1-4 repeats of a 68-bp element in the promoter region of the PDYN gene has been identified. We analyzed this polymorphism of the PDYN gene by a case-control association study in 143 patients with methamphetamine dependence and 209 healthy controls in the Japanese population. A 3- or 4-repeat allele in the PDYN gene promoter was found significantly more frequently in patients with methamphetamine dependence than in controls (χ2 = 9.45, p = 0.0021). A 3- or 4-repeat allele in the PDYN gene promoter, which was shown to produce significantly higher transcription activity of the PDYN gene than a 1- or 2-repeat allele, is a genetic risk factor for development of methamphetamine dependence (odds ratio: 1.83, 95% CI = 1.24-2.68).
AB - Previous studies have indicated that genetic factors substantially affect development of substance use disorders, including methamphetamine dependence. Prodynorphin (PDYN) is an opioid peptide precursor that yields dynorphins, endogenous κ opioid-receptor agonists that play important roles in substance abuse. A physiologically active polymorphism of 1-4 repeats of a 68-bp element in the promoter region of the PDYN gene has been identified. We analyzed this polymorphism of the PDYN gene by a case-control association study in 143 patients with methamphetamine dependence and 209 healthy controls in the Japanese population. A 3- or 4-repeat allele in the PDYN gene promoter was found significantly more frequently in patients with methamphetamine dependence than in controls (χ2 = 9.45, p = 0.0021). A 3- or 4-repeat allele in the PDYN gene promoter, which was shown to produce significantly higher transcription activity of the PDYN gene than a 1- or 2-repeat allele, is a genetic risk factor for development of methamphetamine dependence (odds ratio: 1.83, 95% CI = 1.24-2.68).
UR - https://www.scopus.com/pages/publications/33646157470
UR - https://www.scopus.com/pages/publications/33646157470#tab=citedBy
U2 - 10.1016/j.neulet.2006.02.038
DO - 10.1016/j.neulet.2006.02.038
M3 - Article
C2 - 16529859
AN - SCOPUS:33646157470
SN - 0304-3940
VL - 400
SP - 158
EP - 162
JO - Neuroscience Letters
JF - Neuroscience Letters
IS - 1-2
ER -
SDG 3 すべての人に健康と福祉を